Methods A retrospective cohort study of 88 NSCLC patients with EGFR mutation positive
treated with gefitinib (n= 59), erlotinib (n= 22), and afatinib (n= 7) was performed in national …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are routinely used
to treat non-small cell lung cancer (NSCLC) in patients with common activating mutations of …

The present retrospective, single-center study evaluated the objective response rate (ORR)
and progression-free survival (PFS) of epidermal growth factor receptor (EGFR) mutation …

Objective: The objective of this study was to compare the efficacies of gefitinib and erlotinib
in treating EGFR-mutated non-small-cell lung cancer (NSCLC) patients. Methods: 319 EGFR …

Objective To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of
patients with advanced EGFR mutation-positive NSCLC. Methods Fifty patients with …

Purpose Whether bevacizumab enhances the effect of the epidermal growth factor receptor
(EGFR) inhibitor gefitinib on EGFR mutant non–small cell lung cancers (NSCLCs) remains …

Introduction: Tyrosine kinase inhibitors gefitinib, erlotinib, and afatinib have been compared
with chemotherapy as first-line therapies for patients with advanced non–small-cell lung …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib,
erlotinib and afatinib are standard first-line treatments for EGFR gene mutation-positive non …

Introduction Non-small cell lung cancer (NSCLC) harbouring EGFR exon 19 deletions or
L858R mutation usually respond to epidermal growth factor receptor–tyrosine kinase …

Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …